Does Rapamycin Treat Cancer in Dogs? What the Studies Actually Show

Short answer: rapamycin is not a proven treatment for cancer in dogs. It acts on mTOR, a pathway that genuinely matters in cancer, and it engages that target in dogs — but the largest, best-designed trial to date found no improvement in survival. Rapamycin is studied in dogs for longevity, which is a different question from treating an existing tumour. If your dog has cancer, the honest advice is to see a veterinary oncologist.

Why rapamycin was expected to help

Cancer cells hijack growth signalling, and mTOR sits at the centre of that signalling — it tells a cell when to grow and divide. Blocking mTOR should, in theory, slow that growth. This is not a fringe idea: mTOR inhibitors are used in specific human cancers, and an early comparative-oncology study in dogs showed rapamycin actually reached its target in tumour tissue (Paoloni et al., PLoS One 2010). The biological rationale was real.

What the pivotal dog trial found

The rationale then had to meet a proper trial. In a prospective study of 324 dogs with appendicular osteosarcoma — one of the most aggressive canine cancers — adding sirolimus (rapamycin) to standard care did not extend the disease-free interval or overall survival (median disease-free interval 204 vs 180 days, not statistically significant) (Fan, LeBlanc et al., Clinical Cancer Research 2021). Blood levels in most dogs stayed below the target used in human oncology.

That is the single most important fact on this page, and it is why no honest source can tell you rapamycin treats cancer in dogs. A well-run trial asked the question directly and the answer was no — at least for osteosarcoma at that dose.

Longevity is a different question

Here is the distinction that matters. Treating a tumour that already exists and lowering the long-term risks of aging are not the same goal. Rapamycin’s stronger evidence is in the second: in laboratory mammals it reliably extends healthy lifespan, and in dogs the NIH-funded TRIAD trial (Dog Aging Project) is testing whether low, once-weekly dosing supports healthy aging (Coleman et al., GeroScience 2025). That trial has not reported its primary results either — so even for longevity, the honest word is under investigation, not proven.

So where does rapamycin fit?

• For a dog that already has cancer: it is not a substitute for oncology. See a veterinary oncologist; surgery, chemotherapy and radiation are the tools with the evidence behind them.
• For a healthy older dog: rapamycin is being studied as a longevity intervention, given once weekly under veterinary direction, with monitoring. That is what Rapavie offers — a longevity programme, not a cancer therapy.

Anyone selling rapamycin to you as a cancer cure is ahead of the evidence. The honest position is narrower, and it is the one worth trusting.

Rapamycin is not a cancer treatment. If your dog has been diagnosed with cancer, a veterinary oncologist is the right first call. If you have a healthy older dog and want to understand veterinarian-directed longevity care, talk to the Rapavie team on WhatsApp — we will tell you honestly whether it makes sense for your dog.